1 The ability of the anti-allergic drugs, sodium cromoglycate (SCG), lodoxamide, traxanox, RU31156 and the P-adrenoceptor agonist sulbutamol to inhibit IgE-dependent histamine and prostaglandin D2 (PGD2) release was assessed using human dispersed lung mast cells. 2 The anti-allergic drugs were weak inhibitors of histamine release, high concentrations (1I00O-I000 M) producing <35% inhibition. Salbutamol produced 39% inhibition at 10 M. 3 The efficacy of both SCG and salbutamol was inversely related to the concentration of anti-IgE used for challenge and to the degree of histamine release. 4 Rapid tachyphylaxis was observed with all anti-allergic drugs but not with salbutamol. 5 Cross-tachyphylaxis was observed between SCG and the other anti-allergic drugs, suggesting a common mechanism of action. No cross-tachyphylaxis was observed between SCG and salbutamol. 6 SCG was significantly (P <0.001) more effective in inhibiting PGD2 than it was histamine release. Preferential inhibition of PGD2 compared with histamine release was less marked (P <0.05) with salbutamol and not significant with the other anti-allergic drugs. 7 Mast cells dispersed by enzymatic digestion of human lung released more histamine on immunological challenge than mechanically dispersed cells obtained by fine chopping of tissue. Enzyme treatment of mechanically dispersed cells removed this difference. Enzymatically and mechanically dispersed cells responded similarly to the inhibitory effects of SCG and salbutamol. 8 Our results suggest that salbutamol is a more effective inhibitor of mediator release from human lung mast cells than anti-allergic drugs. However, with the low levels of mediator release achieved during an allergic reaction in man in vivo, both salbutamol and SCG are likely to be effective inhibitors of both preformed and newly generated mediators.
Introduction
The ability of sodium cromoglycate (SCG) and Padrenoceptor agonists to prevent the immediate bronchoconstrictor response to inhaled allergen is well established. The primary mechanism for SCG has been suggested to be inhibition of the release of bronchoconstrictor mediators from broncho-pulmonary mast cells (Cox, 1967) . In support of this mechanism, two studies in vivo have shown some inhibition by SCG ofincreased circulating histamine and neutrophil chemotactic activity (NCA) following antigen challenge of mild asthmatics (Atkins et al., 1978;  'Author for correspondence. 2Present address: Department of Pharmacology, Research Laboratories, Fujisawa Pharmaceutical Co. Ltd, [1] [2] [3] [4] [5] [6] Kashima 2-chome, Yodogawaku, Osaka 532, Japan. Howarth et al., 1985) . Although P-adrenoceptor agonists such as salbutamol are considered to relieve bronchoconstriction primarily by relaxing bronchial smooth muscle, these drugs also reduce increases in circulating histamine levels after antigen challenge (Martin et al., 1980; Howarth et al., 1985) .
Satisfactory models to define the actions ofdrugs on mast cell mediators have been hampered by the heterogeneity of this cell both between and within species. In rat connective tissue mast cells from the peritoneum in vitro (Cox, 1967) and in the skin in vivo (Goose & Blair, 1969) SCG is an effective inhibitor of mediator release. However, rapid tachyphylaxis develops to its actions (Sung et al., 1977a,b) and crosstachyphylaxis with related drugs is taken as an indication of them having the same mechanism of action as SCG (Marshall et al., 1976) . In contrast, rat mucosal mast cells isolated from the lamina propria of the intestine are refractory to the inhibitory effects of SCG (Pearce et al., 1982) . In the guinea-pig, IgE-mediated anaphylaxis is partially inhibited by SCG whereas IgG-mediated reactions are not (Taylor & Roitt, 1973; Carney, 1976) . In the mouse, SCG is ineffective regardless of the antibody mediating the reaction (Miller, 1976) . Histamine releasing cells of man, like those of the rat, show heterogeneity with respect to the action of SCG. Human basophil leucocytes (Church, 1982) and skin mast cells (Ting et al., 1983; Clegg et al., 1985) are refractory to its inhibitory effects. Immunological histamine release from human lung fragments is partially inhibited by SCG (Butchers et al., 1979; , but the variability of this model makes quantification of responses difficult . Studies using bronchoalveolar lavage (BAL) mast cells suggest SCG to be active in inhibiting histamine release Leung et al., 1985) .
A different profile of activity is seen with P-adrenoceptor agonists. In rat mast cells they are usually inactive against histamine release despite their ability to raise intracellular levels of adenosine 3': 5'-cyclic monophosphate (cyclic AMP) (Johnson & Moran, 1970; Marquardt & Wasserman, 1982) . In human and guinea-pig lung fragments, P-adrenoceptor agonists are potent inhibitors of histamine release (Assem & Richter, 1971; Butchers et al., 1979; Peters et al., 1982; and in purified human lung mast cells fenoterol is an effective inhibitor of IgEdependent histamine release at concentrations below 1 pM (Peters et al., 1982) . In contrast, P-adrenoceptor agonists inhibit histamine release from human basophil leucocytes only when they are challenged under unphysiological conditions (Lichtenstein & De Bernardo, 1971 .
Enzymatically dispersed lung cells (EDLC), used for the majority of the experiments, were obtained by digestion of the tissue fragments for 30 min at 37'C with pronase, 2 mg ml -, and chymopapain, 0.5mg ml-' . The isolated cells were separated by sieving as described above and the remaining tissue redigested for another 30 min. The cells from the two digests were pooled, washed and resuspended in HBSS. Mast cell numbers were assessed by counting in a Neubauer haemocytometer after metachromatic staining with Kimura stain (Kimura et al., 1973) .
Histamine release experiments and assay
Immunological histamine release was assessed in duplicate aliquots of 2-4 x 104 mast cells incubated for 15 min with the appropriate concentration of antiIgE. Reactions were terminated by addition of 0.5 ml ice-cold calcium-free HBSS and centrifugation at 250 g for Omin at 4°C. The supernatant was acidified to 5% trichloroacetic acid (TCA) and histamine measured spectrofluorimetrically (Fitzpatrick & Wynalda, 1983) , FCS was omitted from the buffer in these experiments. PGD2 was measured in duplicate 0.1 ml aliquots of cell supernatant or diluted cell supernatant to which 0.1 ml of [3H]-PGD2 (10,000d.p.m.) had been added followed by 0.1 ml of a 1/100 dilution of anti-PGD2 serum. After incubation overnight at 4°C, 0.2 ml of dextran coated charcoal was added and the tubes centrifuged at 1500 g for 15 min at 4°C. The supernatant was removed and 3H counted by liquid scintillation spectrometry. The limit of detection of PGD2 in this assay was 1Opg per tube.
Materials
Sodium cromoglycate (SCG) was donated by Fisons Pharmaceuticals, U.K., lodoxamide by the Upjohn Co. U.S.A., traxanox by Yoshitomi Pharmaceutical Industries Ltd, Japan, RU3 1156 (7-(s-methylsulphonimidoyl)-5-(n-hexyl)-xanthen-9-one-2-carboxylic acid tris-(hydroxymethyl)-aminoethane salt) by Roussel Labs., U.K. and salbutamol by Glaxo Group Research, U.K. Goat anti-human IgE was heat inactivated by incubation at 56'C for I h . Deoxyribonuclease (DNase, bovine pancreas), chymopapain (papaya latex), pronase (Streptomyces griseus) and N-2-hydroxyethyl-piperazine-N'-2-ethanesulphonic acid (HEPES) were purchased from Sigma, U.K. Foetal calf serum (FCS) was obtained from GIBCO, Scotland. Rabbit anti-prostaglandin D2 serum was purchased from Dr L. Levine, Brandeis University, Waltham, M.A., U.S. A. and [5,6,8,9,12,14,15, (n) -3H]-PGD2 (100 Ci mmol') from Amersham International, U.K. All other chemicals were purchased from BDH, Poole, U.K. The composition of HEPES buffered salt solution (HBSS) was (in mM): sodium chloride 137, glucose 5.5, sodium dihydrogen phosphate 0.4, potassium chloride 2.7, magnesium chloride 0.5, calcium chloride 0.9 and HEPES 10. The pH was adjusted to 7.4 with 2 M sodium hydroxide and 2.0% FCS added.
anti-IgE (I %) challenge. With SCG, activity waned as the preincubation time of drug with cells before challenge was increased up to 15 min. Similar effects were observed with lodoxamide, traxanox and RU31156. With longer preincubation periods, there was a tendency for the anti-allergic drugs to 'regain' their efficacy, a phenomenon more marked with traxanox and RU31156.
Salbutamol was also maximally active when added to the cells simultaneously with anti-IgE. Although its activity also waned with extended preincubation periods (Figure 1 ), this was gradual and did not have the characteristics observed with the anti-allergic drugs.
Concentration-response studies Figure 2 shows the results of concentration-response studies when drugs were added to the dispersed lung cells simultaneously with anti-IgE (1%) challenge. High concentrations of anti-allergic drugs were required to observe significant inhibition. SCG produced only 24.6 ± 4.7% inhibition of histamine release at 10001iM. Lodoxamide was a little more active, producing 33.2 ± 6.2% inhibition at 1000 I1M. 
Time-course studies
As rapid tachyphylaxis is a consistent feature of the action of anti-allergic drugs in rat mast cells (Sung et al., 1977a,b) , initial experiments were performed to define the optimal preincubation time for human lung mast cells with inhibitory drugs. The results (Figure 1) show that in seven experiments all drugs tested were maximally active when added simultaneously with Figure 1 Time course for inhibition of IgE-dependent histamine release from human enzymatically dispersed lung cells by (0) sodium cromoglycate (100pM), (A) lodoxamide (100 yM), (V) traxanox (100pM), (-) RU31156 (100I M) and (0) The possibility that drugs could preferentially inhibit the release of a newly generated mediator, PGD2, was examined in four experiments (Figure 4 ). SCG at 1000 pM was significantly (P <0.001) more effective in suppressing PGD2 release, 84.8 ± 6.1% inhibition, than histamine release, 24.8 ± 3.8% inhibition. With lodoxamide, traxanox and RU31156, the inhibitions of histamine and PGD2 release were not statistically different. Salbutamol also showed a preferential inhibition of PGD2 generation (P < 0.05), but this was less marked than with SCG. With salbutamol, histamine release was inhibited by 31.6 ± 2.2% and PGD2 by 65.0 ± 10.2%.
Cross-tachyphylaxis
In rat mast cell experiments, the demonstration of cross-tachyphylaxis between SCG-like compounds is taken as an indicator that they have the same mechanism of action (Marshall et al., 1976 Student's t test for paired data showed significant differences between inhibition of histamine and PGD2 release for SCG (P < 0.001) and salbutamol (P < 0.05).
Influence ofdispersal method
To investigate whether drug effects are influenced by the exposure of cells during enzymatic dispersion or whether mechanical and enzymatic dispersion methods yielded different subpopulations of mast cells, the two methods were compared. In four experiments, both mechanically (MDLC) and enzymatically (EDLC) dispersed lung cells prepared from the same lung samples showed a concentration-related release of histamine following challenge with anti-IgE ( Figure  Sa) . Multivariate analysis revealed that EDLC released significantly (P <0.001) more histamine than did MDLC. That enzyme treatment was more likely to be revealing additional functional IgE-receptors rather than dispersing a different subpopulation of mast cells was suggested by four further experiments in which treatment of MDLC with pronase and chymopapain significantly (P <0.005) enhanced their ability to release histamine upon incubation with antiIgE ( Figure Sb) .
The effects of SCG and salbutamol on IgE-dependent histamine release from MDLC and EDLC were examined in three experiments ( Table 2) . The results show no significant differences between the effects of drugs on the two cell populations. 20.8 ± 6.0 32.4 ± 11.3 50.8 ± 9.1 54.9 ± 6.0 66.2 ± 5.9 EDLC 18.2± 7.5 19.8 ± 6.3 25.9 ± 6.5 49.5 ± 5.9 59.8 ± 6.2 64.3 ± 2.4
Each result is the mean ± s.e.mean of three experiments in which drugs were added to cells simultaneously with anti-IgE, 0.3%, challenge.
Mean control net histamine release for MDLC was 14.0 ± 5.0% and spontaneous release 12.8 ± 2.1%.
Corresponding values for EDLC were 18.2 ± 9.2% and 12.0 ± 3.1%, respectively. There were no significant differences between MDLC and EDLC. Experiments using enzymatically dispersed human lung mast cells have shown SCG to be a weak inhibitor of histamine release, high concentrations being required for significant activity. These results confirm observations using human lung fragments (Butchers et al., 1979; but contrast with results obtained in rat mast cells (Goose & Blair, 1969; Sung et al., 1977a) . In comparison, the 13-adrenoceptor agonist, salbutamol, was more effective, producing a greater inhibition of histamine release at lower concentrations, again confirming previous reports using lung fragments (Butchers et al., 1979; and consistent with the effects of fenoterol in purified lung mast cells (Peters et al., 1982) . Comparison of the concentrations required to produce 25% inhibition of histamine in all experiments where both drugs were used, suggested salbutamol to be between 2000 and 30,000 times more potent than SCG.
Comparisons of the effects of SCG and related drugs in human and rat mast cell preparations show both similarities and differences. The most obvious similarity is the development of rapid tachyphylaxis, a phenomenon repeatedly found for rat mast cells (Sung et al., 1977a,b) which is suggested to be associated with its mechanism of action, i.e. the transient appearance of a phosphorylated 78,000 dalton protein which inhibits mediator release (Theoharides et al., 1980; Wells & Mann, 1983) . A second similarity is the presence of cross-tachyphylaxis between SCG and related drugs (Marshall et al., 1976) . Thus, the observation that preincubation of cells with SCG significantly reduced the subsequent effects of lodoxamide, traxanox and RU3 1156 suggests that they inhibit histamine release from human lung mast cells by a similar mechanism. This mechanism is obviously related to that of salbutamol which showed no crosstachyphylaxis with SCG. Differences between the effects of SCG and related drugs in rat and human lung mast cells are the high concentrations required and the weak inhibitory effect in human cells (Goose & Blair, 1969) . Furthermore, SCG, lodoxamide, traxanox and RU31156 have similar potencies in human lung mast cells whereas in the rat PCA test (which is indicative of activity in rat connective tissue mast cells) their potencies are widely differing being (based on SCG = I); lodoxamide 2500 (Johnson et al., 1978) , traxanox 8 (Goto et al., 1979) and RU31156 260 (Miller & James, 1978) .
Immunological activation of human lung mast cells not only releases histamine but also leads to the synthesis and release of PGD2 (Holgate et al., 1984) and sulphidopeptide leukotrienes (MacGlashan et al., 1982) . Although leukotrienes may also be released from other cells within the dispersed samples (Damon et al., 1983) , the mast cell is the only source of PGD2 (Holgate et al., 1984) . Our observation that SCG inhibits the release of PGD2 more effectively than that of histamine, therefore, reflects a differential inhibition of mediator release within the same cell population. The differences between inhibition of histamine and PGD2 liberation were not significantly different with the other anti-allergic drugs tested. Even though PGD2 is a potent bronchoconstrictor prostaglandin in man (Hardy et al., 1984) , it is not clear how inhibition of PGD2 production relates to its clinical efficacy. However, it is noteworthy that while both SCG and lodoxamide inhibit the early asthmatic reaction to bronchial provocation (Cox & Altounyan, 1970; Watt et al., 1980) , lodoxamide has little activity against clinical asthma (Mann et al., 1985) .
The inhibitory effects of salbutamol and SCG were inversely related to the intensity of immunological stimulation and, consequently, to histamine release. With salbutamol, the slopes of the concentrationinhibition curves and the maximum inhibition of histamine release were inversely related to the strength ofimmunological stimulation. However, the maximally effective concentration, I to 1O pM, remained constant. These results are consistent with the findings of Tung & Lichtenstein (1981) that the inhibitory capacity of agents which elevate intracellular cyclic AMP is more pronounced at low levels of histamine release. The observation of a similar relationship with SCG suggests that these characteristics also apply to agents utilizing cyclic GMP as an intracellular messenger (Wells & Mann, 1983) . As, in comparison to in vitro tests, the level of immunological stimulation and consequential histamine release during allergic reactions in man in vivo are low (Howarth et al., 1985) , it is likely that both salbutamol and SCG would be effective inhibitors ofmast cells mediator release in the clinical situation.
Recent findings suggest that SCG is more effective in inhibiting histamine release in mast cells removed from the lung by bronchoalveolar lavage (BAL) than it is in cells dispersed from lung tissue 
